Systematic Evaluation of Osimertinib Population Pharmacokinetic Models in a Cohort of Dutch Adults with Non-Small Cell Lung Cancer [0.03%]
奧希替尼人群药代动力学模型的系统评估——荷兰非小细胞肺癌成人患者队列研究
Niels Westra,Paul D Kruithof,Sander Croes et al.
Niels Westra et al.
Background and objective: Several population pharmacokinetic (popPK) studies have been reported that can guide the prediction of osimertinib plasma concentrations in individual patients. It is currently unclear which popP...
Model-Based Bioequivalence Analysis to Assess and Predict the Relative Bioavailability of Valproic Acid Formulations [0.03%]
基于模型的生物等效性分析评估和预测丙戊酸盐制剂的相对生物利用度
Alejandra Schiavo,Pietro Fagiolino,Marta Vázquez et al.
Alejandra Schiavo et al.
Background and objective: Model-based bioequivalence (MBBE) encompasses the use of nonlinear mixed effect models supporting the estimation of pharmacokinetic endpoints to assess the relative bioavailability between multi-...
Randomized Controlled Trial
European journal of drug metabolism and pharmacokinetics. 2024 Jul;49(4):507-516. DOI:10.1007/s13318-024-00901-8 2024
Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II) [0.03%]
基于群体药代动力学模型和模拟的帕利哌酮棕榈酸酯6个月注射剂用于精神分裂症患者的以模型为驱动的临床开发（第二部分）：给药策略指导
Huybrecht T&#x;jollyn,Raja Venkatasubramanian,Martine Neyens et al.
Huybrecht T&#x;jollyn et al.
Background and objective: Paliperidone palmitate 6-month (PP6M) intramuscular (IM) injection is the longest-acting treatment available for patients with schizophrenia. A population pharmacokinetic (popPK) modeling and sim...
Model-Informed Clinical Development of Once-Every-6-Month Injection of Paliperidone Palmitate in Patients with Schizophrenia: A Pharmacometric Bridging Approach (Part I) [0.03%]
基于模型的帕利哌酮棕榈酸酯长效注射制剂治疗精神分裂症患者的每6个月1次注射给药临床开发桥接研究（一）
Huybrecht T&#x;jollyn,Alberto Russu,Raja Venkatasubramanian et al.
Huybrecht T&#x;jollyn et al.
Background and objective: A model-informed drug development (MIDD) approach was implemented for paliperidone palmitate (PP) 6-month (PP6M) clinical development, using pharmacokinetics and pharmacokinetic/pharmacodynamic m...
Comparative Pharmacokinetic Study of Standard Astaxanthin and its Micellar Formulation in Healthy Male Volunteers [0.03%]
标准虾青素及其米勒体系制剂在健康男性受试者中的比较药代动力学研究
Mohamed T Khayyal,Mahmoud H Teaima,Hoda M Marzouk et al.
Mohamed T Khayyal et al.
Background and objective: Astaxanthin is a naturally occurring carotenoid with high anti-oxidant properties, but it is a very lipophilic compound with low oral bioavailability. This study was conducted to compare the phar...
Randomized Controlled Trial
European journal of drug metabolism and pharmacokinetics. 2024 Jul;49(4):467-475. DOI:10.1007/s13318-024-00898-0 2024
Prediction of the First-Pass Metabolism of a Drug After Oral Intake Based on Structural Parameters and Physicochemical Properties [0.03%]
基于结构参数和物理化学性质预测口服药物的一次代谢率
Mir Amir Hossein Hosseini,Ali Akbar Alizadeh,Ali Shayanfar
Mir Amir Hossein Hosseini
Background and objective: The oral first-pass metabolism is a crucial factor that plays a key role in a drug's pharmacokinetic profile. Prediction of the oral first-pass metabolism based on chemical structural parameters ...
Influence of UGT2B7, UGT1A4 and ABCG2 Polymorphisms on the Pharmacokinetics and Therapeutic Efficacy of Lamotrigine in Patients with Epilepsy [0.03%]
UGT2B7、UGT1A4和ABCG2多态性对癫痫患者加巴喷丁药动学及疗效影响的研究
Jing Yang,Jinxingyi Wang,Lijie Ning et al.
Jing Yang et al.
Background and objectives: A substantial inter-individual variability has been observed in the pharmacokinetics of lamotrigine. The aim of the study was to investigate the impact of genetic polymorphism of the metabolizin...
Does Sample Size, Sampling Strategy, or Handling of Concentrations Below the Lower Limit of Quantification Matter When Externally Evaluating Population Pharmacokinetic Models? [0.03%]
当外部评估人群药代动力学模型时样本量、抽样策略或如何处理低于定量下限的浓度重要吗？
Mehdi El Hassani,Uwe Liebchen,Amélie Marsot
Mehdi El Hassani
Background and objectives: Precision dosing requires selecting the appropriate population pharmacokinetic model, which can be assessed through external evaluations (EEs). The lack of understanding of how different study d...
The Use of Microdosing for In vivo Phenotyping of Cytochrome P450 Enzymes: Where Do We Stand? A Narrative Review [0.03%]
微剂量在体表型化细胞色素P450酶中的应用：我们目前处于什么阶段？叙述性综述
Lisa T van der Heijden,Frans L Opdam,Jos H Beijnen et al.
Lisa T van der Heijden et al.
Cytochrome P450 (CYP) enzymes play a central role in the elimination of approximately 80% of all clinically used drugs. Differences in CYP enzyme activity between individuals can contribute to interindividual variability in exposure and, th...
Uridine 5'-Diphospho-glucuronosyltransferase 1A3 (UGT1A3) Prediction of Hepatic Clearance of Organic Anion Transporting Polypeptide 1B3 (OATP1B3) Substrate Telmisartan by Glucuronidation Using In Vitro-In Vivo Extrapolation (IVIVE) [0.03%]
有机阴离子转运多肽1B3（OATP1B3）底物坦洛普坦的体内葡糖醛酸化清除率预测：体外-体内推算(IVIVE)研究尿苷5'-二磷酸葡萄糖醛酸转移酶1A3 (UGT1A3)的作用
Ewelina Gabor-Worwa,Anna Kowal-Chwast,Nilesh Gaud et al.
Ewelina Gabor-Worwa et al.
Background and objective: The prediction of pharmacokinetic parameters for drugs metabolised by cytochrome P450 enzymes has been the subject of active research for many years, while the application of in vitro-in vivo ext...